event,time
32 years old ,0.0
    woman ,0.0
    diagnosed with JAK2 mutation-negative essential thrombocythemia (ET) ,-144000.0
    treated by pipobroman for 7 years ,-144000.0
    treated by hydroxyurea for 4 years ,-144000.0
    treated by anagrelide for 3 years ,-144000.0
    began complaining about asthenia ,-1464.0
    gradual decrease in hemoglobin level ,-1464.0
    anagrelide stopped ,-1464.0
    bone marrow biopsy performed ,-720.0
    occurrence of grade 2 myelofibrosis ,-720.0
    hematologic tests revealed more than 20% blastic cells in peripheral blood ,-504.0
    ET with myelofibrosis evolved into acute myeloid leukemia ,-504.0
    received allogeneic bone marrow hematopoietic stem-cell transplantation (HSCT) ,0.0
    admitted to intensive care unit (ICU) for acute respiratory distress syndrome (RDS) ,0.0
    blood cultures yielded Staphylococcus aureus ,0.0
    blood cultures yielded Escherichia coli ,0.0
"    broad-spectrum antibiotherapy (tazobactam/piperacillin, amikacin, vancomycin) ",0.0
    furosemide for acute pulmonary edema ,0.0
    rapid improvement of patient condition ,0.0
    oral fluconazole prophylaxis (400 mg/day) started ,0.0
    readmitted to ICU for acute RDS ,12.0
    septic shock with no microbiological evidence of infection ,12.0
"    became afebrile after empirical antibiotherapy (ceftazidime, linezolid) ",12.0
    presented with first symptoms of Graft-versus-Host Disease (GvHD) ,37.0
    GvHD developed to skin ,37.0
    GvHD developed to gastrointestinal tract ,37.0
    GvHD developed to liver ,37.0
    received corticosteroids ,37.0
    received inolimomab ,37.0
    received sirolimus ,37.0
    received basiliximab ,37.0
    digestive disorders remained chronic ,37.0
    hemorrhagic manifestations ,37.0
    readmitted to ICU for similar respiratory symptomatology ,63.0
"    new antibiotic regimen (imipenem, ciprofloxacin, ceftriaxone) ",63.0
    intravenous caspofungin (50 mg/day) started ,63.0
    routine microbiological surveillance cultures performed weekly ,63.0
    Candida albicans isolated from oropharynx swab ,-1464.0
    Candida albicans isolated from rectal swab or stools ,-1464.0
    Candida albicans isolated from urine ,-1464.0
    Candida albicans no longer isolated ,0.0
    colonization of gastrointestinal tract by C. kefyr ,0.0
    colonization of urinary tract by C. kefyr ,0.0
    increasing fungal load ,0.0
    caspofungin stopped ,0.0
    oral fluconazole (400 mg/day) restarted ,0.0
    neutropenic patient suffered from unexplained fever ,0.0
    thoracic computed tomography (CT) performed ,0.0
    CT imaging showed pulmonary nodules suspected to be pulmonary aspergillosis ,0.0
    antifungal therapy switched to voriconazole ,0.0
    serum galactomannan (GM) assay performed twice a week ,0.0
    GM assay index on bronchoalveolar lavage (BAL) was negative ,0.0
    BAL culture yielded no Aspergillus ,0.0
    BAL culture yielded heavy growth of C. kefyr ,0.0
    blood cultures remained negative ,0.0
    no other pathogen found ,0.0
    measurement of (1→3)-β-d-glucan antigenemia revealed elevated serum concentration (411 pg/mL) ,0.0
    possible deep candidiasis suspected ,0.0
    treatment with caspofungin resumed ,0.0
    follow-up CT showed increase in size and number of pulmonary lesions ,0.0
    readmitted to ICU with acute renal failure ,0.0
    died of multiple organ failure ,168.0
    Explanation:,
"The answer provided includes a detailed table of clinical events and their corresponding timestamps based on the case report. The admission event (HSCT on Day 0) is assigned timestamp 0. Events prior to admission are given negative timestamps, while those after admission are positive. The timestamps are estimated using the information provided in the case report and converting days into hours. For example:",
"- The diagnosis of JAK2 mutation-negative essential thrombocythemia (ET) occurred in 1997, which is approximated to a timestamp of -144000 hours (16 years prior to admission).",
),
